SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs
Over four years have passed since the beginning of the COVID-19 pandemic. The scientific
response has been rapid and effective, with many therapeutic monoclonal antibodies and …
response has been rapid and effective, with many therapeutic monoclonal antibodies and …
Predicting antiviral resistance mutations in SARS-CoV-2 main protease with computational and experimental screening
The main protease (Mpro) of SARS-CoV-2 is essential for viral replication and has been the
focus of many drug discovery efforts since the start of the COVID-19 pandemic. Nirmatrelvir …
focus of many drug discovery efforts since the start of the COVID-19 pandemic. Nirmatrelvir …
Efficacy of late-onset antiviral treatment in immunocompromised hosts with persistent SARS-CoV-2 infection
CM Lieber, HJ Kang, EB Sobolik, ZM Sticher… - Journal of …, 2024 - journals.asm.org
Immunocompromised people are at high risk of prolonged severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection and progression to severe coronavirus …
syndrome coronavirus 2 (SARS-CoV-2) infection and progression to severe coronavirus …
A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system
F Costacurta, A Dodaro, D Bante, H Schöppe… - PLoS …, 2024 - journals.plos.org
Nirmatrelvir was the first protease inhibitor specifically developed against the SARS-CoV-2
main protease (3CLpro/Mpro) and licensed for clinical use. As SARS-CoV-2 continues to …
main protease (3CLpro/Mpro) and licensed for clinical use. As SARS-CoV-2 continues to …
A low-background, fluorescent assay to evaluate inhibitors of diverse viral proteases
RA Leonard, VN Rao, A Bartlett, HM Froggatt… - Journal of …, 2023 - Am Soc Microbiol
Multiple coronaviruses (CoVs) can cause respiratory diseases in humans. While
prophylactic vaccines designed to prevent infection are available for severe acute …
prophylactic vaccines designed to prevent infection are available for severe acute …
Inhibition of endocytic uptake of severe acute respiratory syndrome coronavirus 2 and endo-lysosomal acidification by diphenoxylate
JS Shin, Y Jang, DS Kim, E Jung, MK Lee… - Antimicrobial Agents …, 2024 - Am Soc Microbiol
Cell culture-based screening of a chemical library identified diphenoxylate as an antiviral
agent against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The …
agent against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The …
Drug susceptibility and the potential for drug-resistant SARS-CoV-2 emergence in immunocompromised animals
The reduced susceptibility of mRNA vaccines and diminished neutralizing activity of
therapeutic monoclonal antibodies against Omicron variants, including BQ. 1.1, XBB, and …
therapeutic monoclonal antibodies against Omicron variants, including BQ. 1.1, XBB, and …
[HTML][HTML] SARS-CoV-2 Mpro inhibitor identification using a cellular gain-of-signal assay for high-throughput screening
R Delgado, J Vishwakarma, SA Moghadasi, Y Otsuka… - SLAS Discovery, 2024 - Elsevier
Abstract Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2, SARS2) is
responsible for the COVID-19 pandemic and infections that continue to affect the lives of …
responsible for the COVID-19 pandemic and infections that continue to affect the lives of …